You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Ultrafast Physical Random Number Generation Using Hybrid Boolean Networks

    SBC: Eno River Technologies Co.            Topic: A14AT002

    Eno River Technologies and Duke University propose to develop Hybrid Boolean Network (HBN) technology for ultrafast physical random number generation. HBNs are circuits composed partly of unclocked logic elements that exhibit chaotic dynamics and clocked elements that provide readout and synchronization to the system bus. It is hypothesized that the chaotic elements amplify electronic noise in t ...

    STTR Phase I 2014 Department of DefenseArmy
  2. Superconducting Parametric Amplifier

    SBC: HYPRES, INC.            Topic: A14AT010

    HYPRES, in collaboration with MIT Lincoln Laboratory and ISQC, proposes to transition superconducting parametric amplifier technology into a robust line of products. In Phase I, we will develop three varieties of superconducting low-noise amplifiers (LNAs) in compact cryogenic microwave packages. These are two types of standing wave devices, lumped-element Josephson parametric amplifier (LJPA) and ...

    STTR Phase I 2014 Department of DefenseArmy
  3. Low Power Monolayer MoS2 Transistors for RF Applications

    SBC: KYMA TECHNOLOGIES, INC.            Topic: A14AT008

    Utilizing a novel solid/gas source CVD reactor designed for the growth of large area (substrates up to 4"in diameter) MoS2 single layer (SL) and multiple layer (ML) films, and leveraging already demonstrated capabilities in the growth and fabrication of 2D-FETs based on graphene and WSe2, we are proposing the growth, fabrication and testing of MoS2-based RF FETs. Utilizing a novel and optimized s ...

    STTR Phase I 2014 Department of DefenseArmy
  4. POC 2-D Diffusion Assay for self-monitoring of BNP

    SBC: SENTILUS            Topic: NHLBI

    DESCRIPTION (provided by applicant): The objective of this STTR proposal is to develop a 2-D diffusion point-of-care assay (POC) for B-type natriuretic peptide (BNP). The primary goal of the proposed work is to create a test format that will allow patientswith chronic heart failure to quantitatively self-monitor serum levels of BNP. Determination of baseline level of BNP and changes in this level ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Science Take-Out Kits for Environmental Health Education

    SBC: Science Take-Out, LLC            Topic: NIEHS

    DESCRIPTION provided by applicant Nearly percent of death and disease worldwide is linked to environmental factors WHO therefore it is critical that the general public has basic understanding of how the environment affects their health and how they might protect themselves against environmental exposures Unfortunately environmental health content is typically covered on a very ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget

    SBC: DOTY SCIENTIFIC, INC.            Topic: NIA

    ? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. New generation of catheters for treatment of atrial fibrillation

    SBC: NOCTURNAL PRODUCT DEVELOPMENT, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Atrial fibrillation remains the most commonly occurring cardiac arrhythmia. It is associated with a lower quality of life and a higher rate of morbidity and mortality. Cryotherapy and radiofrequency catheter ablations for the purpose of eliminating atrial fibrillation have become a mainstream treatment option. They produce lesions that block the spread of elect ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. A novel therapeutic approach for Acute Lung Injury/ARDS

    SBC: BIOMARCK PHARMACEUTICALS, LTD            Topic: NHLBI

    DESCRIPTION (provided by applicant): The objective of the proposed project is to advance the development of novel peptides targeting MARCKS (Myristoylated Alanine-Rich C Kinase Substrate) protein as platform drug molecules for the treatment of Acute Lung Injury (ALI) and its more severe form, Acute Respiratory Distress Syndrome (ARDS), thereby providing the first pharmacologic therapeutic for this ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Focal Adhesion Kinase autophosphorylation inhibitors against pancreatic cancer

    SBC: CUREFAKTOR PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Due to the absence of effective therapies, pancreatic cancer is the fourth leading cause of cancer deaths in both men and women. This study focuses on the development of new small molecule inhibitors targeting Focal Adhesion Kinase against pancreatic cancer. Focal Adhesion Kinase (FAK) has been shown to play an important role in tumor cell survival, including p ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Evaluation of TRB-N0224, a Proprietary Chemically-Modified Curumin, for the Treat

    SBC: TRAVERSE BIOSCIENCES, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): Traverse Biosciences Inc. is a pre-clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host-modulation of pathologically unrestrained matrix metalloproteinases (MMPs) and pro-inflammatory cytokines. The company's lead drug candidate, TRB-N0224, is a proprie ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government